An interventional study of EIAU and LICF in Depression, Postpartum, sponsored by Michigan State University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Michigan State University · Not applicable, Interventional, and Prevention
Postpartum depression (PPD) is common and can have lasting consequences for mother and child. ROSE is an intervention to prevent PPD, delivered during pregnancy in outpatient prenatal settings. ROSE has been found to significantly reduce cases of PPD in multiple randomized trials in community prenatal settings with racially and ethnically diverse low-income pregnant women. Requests for ROSE training and recent policy changes supporting payment for comprehensive perinatal services to underserved populations suggest a context ripe for embedding ROSE in prenatal clinics long-term. Given the need for return on investment studies about sustainment efforts, we propose a Sequential Multiple Assignment Randomized (SMART) Trial of the effectiveness and cost-effectiveness of a stepwise approach to sustainment of ROSE in 90 outpatient clinics providing prenatal care to pregnant women on public assistance in 6 U.S. states. In Year 1, all clinics will receive enhanced implementation as usual (EIAU; initial training + tools for sustainment). At the first time at which a clinic is determined to be at risk for failure to sustain (i.e., at 3, 6, 9, 12, 15 months), that clinic will be randomized to receive either: (1) no additional implementation support (i.e., EIAU only), or (2) low-intensity coaching and feedback (LICF). If clinics receiving LICF are still found to be at risk at subsequent assessments, they will be randomized to either (1) EIAU + LICF only, or (2) high-intensity coaching and feedback (HICF). Additional study follow-up interviews will occur at 18, 24, and 30 months, but no implementation intervention will occur after 18 months. Outcomes include: 1. Sustainment of core program elements at each time point and total length of time ROSE services were provided and were provided with at least moderate fidelity. 2. Health impact (PPD rates over time at each clinic) and reach. 3. ROI (costs, cost-offsets, and cost-effectiveness) of each sustainment step. Hypothesized mechanisms include sustainment of clinical and organizational capacity to deliver core elements, and engagement/ownership. The study will also examine predictors, tailoring variables, and implementation processes to determine which kinds of clinics need which level of sustainment support and when. To our knowledge, this study will be the first randomized trial evaluating the ROI of a stepped approach to sustainment, a critical unanswered question in implementation science.
A recent expert consensus report concluded that, "Little is known about how well or under what conditions health innovations are sustained and their gains maintained once they are put into practice. Implementation science typically focuses on uptake by early adopters. The later-stage challenges of sustaining evidence-supported interventions receive too little attention." This report placed high priority on conducting return on investment (ROI) studies to determine how much is gained when effective programs are sustained, and cost-benefit trade-offs for effort required to sustain.1 Information is especially needed for preventive behavioral health interventions for adults in outpatient medical (e.g., primary care; OBGYN) settings.
Postpartum depression (PPD) is common and can have serious and lasting consequences for mother and child, including maternal increased risk for suicide, compromised functional status, and adverse infant developmental outcomes. Prevalence of PPD is \~13% in the 12 weeks after childbirth, with rates up to 50% among low-income women, who are especially vulnerable to the consequences of PPD. Outpatient clinics offering prenatal care are an opportune place to deliver PPD prevention services because most women will visit while pregnant. Recent guidelines suggest that prenatal clinics should screen for PPD after birth and refer once it is identified. Unfortunately, prenatal clinics do not routinely do anything to prevent PPD from occurring.
The ROSE Program (Reach Out, Stay Strong, Essentials for mothers of newborns) is a small-group intervention to prevent PPD that is delivered during pregnancy in outpatient prenatal settings. ROSE is the only PPD preventative intervention that (1) has been found to significantly reduce cases of PPD in multiple randomized trials, and (2) has been tested in community prenatal settings with racially and ethnically diverse low income pregnant women. ROSE consists of four 90-minute group sessions and a 50-minute individual booster session after delivery. Requests for ROSE training in Philadelphia and nationwide in Japan, and recent policy changes supporting payment for comprehensive perinatal services (including behavioral health care) to underserved populations all suggest a context ripe for embedding ROSE in prenatal clinics long-term. Given the need for ROI studies about sustainment efforts and that ROSE is well-positioned for implementation and sustainment research, we propose a Sequential Multiple Assignment Randomized (SMART) Trial of the effectiveness and cost-effectiveness of a stepwise approach to sustainment of ROSE in 90 outpatient clinics providing prenatal care to pregnant women on public assistance accross the US. Our conceptual framework comes from RE-AIM and a review on sustainment by Co-I Wiltsey-Stirman,3 with sustainment strategies based on the Replicating Effective Programs (REP) framework. All clinics will receive enhanced implementation as usual (EIAU; initial training + tools for sustainment). Clinics will be assessed using surveys and qualitative interviews 9 times over 2.5 years after receiving EIAU. Clinics at risk for failure to sustain operationally (defined as no ROSE intervention in 3 months and none planned) and/or clinically (defined as low fidelity to ROSE core elements) will be randomized to receive additional sustainment support for up to 18 months after baseline. At the first time period at which a clinic is determined to be at risk (i.e., at 3, 6, 9, 12, or 15 months), that clinic will be randomized to receive either: (1) no additional implementation support (EIAU only), or (2) EIAU plus low-intensity (every 3 months) coaching and feedback (LICF). If clinics receiving LICF are still at risk at subsequent monitoring periods, they will be randomized to (1) EIAU + LICF only, or (2) EIAU + LICF + high-intensity (monthly) coaching and feedback (HICF). Additional study follow-up interviews will occur at 18, 24, and 30 months, but no implementation intervention will occur after 18 months. We will assess costs and benefits of sustainment strategies. Aims are to:
Compare effectiveness of each sustainment step for the following final and proximal OUTCOMES:
To our knowledge, this study will be the first randomized trial evaluating the ROI of a stepped approach to sustainment, a critical unanswered question in implementation science. The study will also examine a set of strategies to promote sustainment of an effective PPD prevention intervention for low-income women, reducing negative consequences for mother and child. The proposal directly addresses the goal of PAR-16-238 to conduct longitudinal studies on "factors that contribute to the sustainability of evidence-based interventions," to test strategies to improve quality of care among underserved populations, examine mediators and moderators, and examine cost-effectiveness or other economic outcomes. Thus, the study will advance implementation science, knowledge of implementation science mechanisms, and clinical care for an at-risk population.
Study enrollment began with enrollment of clinics. Inclusion criteria for clinics were:
Participants were clinic personnel, and they were enrolled within clinic. Their inclusion criteria were:
Exclusion Criteria:
EIAU: Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment.
Behavioral: EIAU · Behavioral: LICF · Behavioral: HICF
Low-intensity (every 3 months) coaching and feedback (LICF): Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone "booster" meeting.
Behavioral: LICF · Behavioral: HICF
High-intensity (every month) coaching and feedback (HICF): Enhanced implementation plus high intensity will have received initial training and problem-solving plus planning for sustainment and after that every month will receive one clinical and one operational telephone "booster" meeting.
Behavioral: HICF
Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment,
Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone "booster" meeting.
Enhanced implementation plus high intensity will receive will receive everything that the clinics in LICF receive, but at a higher intensity.
Proportion Sustainment of Core Program Elements
Proportion sustainment of ROSE's core program elements, assessed using the ROSE Session-by-Session Adherence Scale, was defined as the mean proportion of core elements delivered that should have been delivered at each ROSE session over the time period (zero if no sessions were completed). Potential range is 0 to 1, higher score reflects better outcome.
Time frame: Average over months 3, 6, 9, 12, 15, 18, 24, and 30 after baseline
Number of Months of Sustained ROSE Delivery
Number of months when ROSE was delivered was tracked using calendar method. Potential range is 0 to 30 months, higher score reflects better outcome.
Time frame: Summary of total number of months over 30 month study period.
Number of Months of Sustained ROSE Delivery With Fidelity
Number of months when ROSE was delivered with fidelity was tracked using calendar method. Potential range is 0 to 30 months, higher score reflects better outcome.
Time frame: Summary of total number of months over 30 month study period.
Annualized Percent of Pregnant People Attending at Least One ROSE Session Over 30 Months
Surveys at each time point included questions for the clinic to report the number of people who attended at least one ROSE session and the number served by the clinic in the past 12 months. Total numbers attending ROSE over 30 months were annualized (divided by 2.5), then divided by number of pregnant people served in the 12 months prior to baseline and multiplied by 100% to estimate percent of pregnant patients at each agency who received ROSE over 30 months. Potential range is 0 to 100 percent. Higher score reflects better outcome.
Time frame: Summary over 30 month study period.
Annualized Percent of Pregnant People Attending at Least Three ROSE Sessions (of Five) Over 30 Months
Surveys at each time point included questions for the clinic to report the number of people who attended at least three ROSE sessions and the number served by the clinic in the past 12 months. Total numbers attending at least three ROSE sessions over 30 months were annualized (divided by 2.5), then divided by number of pregnant people served in the 12 months prior to baseline and multiplied by 100% to estimate percent of pregnant patients at each agency who received at least three sessions of ROSE over 30 months. Potential range is 0 to 100 percent. Higher score reflects better outcome.
Time frame: Summary over 30 month study period.
| Milestone | EIAU Only Responders | EIAU Only Followed by Continued EIAU Only for Non-responders to Initial EIAU | EIAU Only Followed by LICF for Non-responders to Initial EIAU, Responders to LICF | EIAU Followed by LICF for Non-responders to EIAU, Non- Responders to LICF Continued With LICF | EIAU Followed by LICF for Non-responders to EIAU, Non- Responders to LICF Also Received HICF | Drop-outs After EIAU+LICF Prior to Determining Response to EIAU+LICF | EIAU Drop-out Prior to Determining Response to EIAU |
|---|---|---|---|---|---|---|---|
| Started | 70 | 18 | 21 | 24 | 24 | 1 | 2 |
| Completed | 70 | 18 | 21 | 24 | 24 | 1 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Proportion sustainment of ROSE's core program elements, assessed using the ROSE Session-by-Session Adherence Scale, was defined as the mean proportion of core elements delivered that should have been delivered at each ROSE session over the time period (zero if no sessions were completed). Potential range is 0 to 1, higher score reflects better outcome.
| proportion of sessions | First Randomization: Participants in 44 Clinics Not Responding to EIAU and Had LICF Added | First Randomization: Participants in 12 Clinics Not Responding to EIAU, Continued With EIAU | Second Randomization: Participants in 15 Clinics Not Responding to LICF+EIAU and Had HICF Added | Second Randomization: Participants in 14 Clinics Not Responding to LICF+EIAU, Continued With LICF |
|---|---|---|---|---|
| Proportion Sustainment of Core Program Elements | 0.34 ± 0.05 | 0.18 ± 0.09 | 0.43 ± 0.08 | 0.13 ± 0.09 |
Number of months when ROSE was delivered was tracked using calendar method. Potential range is 0 to 30 months, higher score reflects better outcome.
| months | First Randomization: Participants in 44 Clinics Not Responding to EIAU and Had LICF Added | First Randomization: Participants in 12 Clinics Not Responding to EIAU, Continued With EIAU | Second Randomization: Participants in 15 Clinics Not Responding to LICF+EIAU and Had HICF Added | Second Randomization: Participants in 14 Clinics Not Responding to LICF+EIAU, Continued With LICF |
|---|---|---|---|---|
| Number of Months of Sustained ROSE Delivery | 7.00 ± 1.09 | 5.07 ± 1.95 | 7.11 ± 1.81 | 3.38 ± 1.87 |
Number of months when ROSE was delivered with fidelity was tracked using calendar method. Potential range is 0 to 30 months, higher score reflects better outcome.
| months | First Randomization: Participants in 44 Clinics Not Responding to EIAU and Had LICF Added | First Randomization: Participants in 12 Clinics Not Responding to EIAU, Continued With EIAU | Second Randomization: Participants in 15 Clinics Not Responding to LICF+EIAU and Had HICF Added | Second Randomization: Participants in 14 Clinics Not Responding to LICF+EIAU, Continued With LICF |
|---|---|---|---|---|
| Number of Months of Sustained ROSE Delivery With Fidelity | 6.02 ± 0.91 | 4.41 ± 1.79 | 6.68 ± 1.45 | 2.20 ± 1.54 |
Surveys at each time point included questions for the clinic to report the number of people who attended at least one ROSE session and the number served by the clinic in the past 12 months. Total numbers attending ROSE over 30 months were annualized (divided by 2.5), then divided by number of pregnant people served in the 12 months prior to baseline and multiplied by 100% to estimate percent of pregnant patients at each agency who received ROSE over 30 months. Potential range is 0 to 100 percent. Higher score reflects better outcome.
| percentage of pregnant people | First Randomization: Participants in 44 Clinics Not Responding to EIAU and Had LICF Added | First Randomization: Participants in 12 Clinics Not Responding to EIAU, Continued With EIAU | Second Randomization: Participants in 15 Clinics Not Responding to LICF+EIAU and Had HICF Added | Second Randomization: Participants in 14 Clinics Not Responding to LICF+EIAU, Continued With LICF |
|---|---|---|---|---|
| Annualized Percent of Pregnant People Attending at Least One ROSE Session Over 30 Months | 1.07 (0 to 4.80) | 0.46 (0.07 to 11.00) | 1.62 (0.10 to 7.67) | 0 (0 to 2.07) |
Surveys at each time point included questions for the clinic to report the number of people who attended at least three ROSE sessions and the number served by the clinic in the past 12 months. Total numbers attending at least three ROSE sessions over 30 months were annualized (divided by 2.5), then divided by number of pregnant people served in the 12 months prior to baseline and multiplied by 100% to estimate percent of pregnant patients at each agency who received at least three sessions of ROSE over 30 months. Potential range is 0 to 100 percent. Higher score reflects better outcome.
| percentage of pregnant people | First Randomization: Participants in 44 Clinics Not Responding to EIAU and Had LICF Added | First Randomization: Participants in 12 Clinics Not Responding to EIAU, Continued With EIAU | Second Randomization: Participants in 15 Clinics Not Responding to LICF+EIAU and Had HICF Added | Second Randomization: Participants in 14 Clinics Not Responding to LICF+EIAU, Continued With LICF |
|---|---|---|---|---|
| Annualized Percent of Pregnant People Attending at Least Three ROSE Sessions (of Five) Over 30 Months | 0.10 (0 to 2.88) | 0.06 (0 to 10) | 0.38 (0 to 4.27) | 0 (0 to 0.01) |
Collected over Each clinic was in the study for 30 months, and adverse event data were collected over 30 months for participants in each clinic.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants in 54 Clinics Receiving EIAU Training Only | 0/90 (0%) | 0/90 (0%) | 0/90 (0%) |
| Participants in 29 Clinics Receiving LICF Training After Non-response to EIAU | 0/46 (0%) | 0/46 (0%) | 0/46 (0%) |
| Participants in 15 Clinics Receiving HICF Training After Non-response to LICF+EIAU | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) |
Clinic personnel from each clinic provided data on their demographic characteristics.
| Age, Continuous(years) | Phase I: Responders to EIAU in 41 Clinics | Phase II: Non-responders to EIAU, Continued EIAU in 12 Clinics | Phase II: Non-responders to EIAU, Responders to Added LICF in 14 Clinics | Phase III: Non-responders to LICF+EIAU, Continued LICF | Phase III: Non-responders to LICF+EIAU, HICF Added | Phase II: LICF After Non-response to EIAU, Dropout Before Response to LICF Can be Determined | Phase I: EIAU, Dropout Before Response to EIAU Can be Determined | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 41.87 ± 10.69 | 39.47 ± 9.43 | 42.75 ± 10.19 | 44.26 ± 12.16 | 46.86 ± 9.67 | 28.00 | 44.5 ± 6.36 | 42.82 ± 10.65 |
| Sex/Gender, Customized(Participants) | Phase I: Responders to EIAU in 41 Clinics | Phase II: Non-responders to EIAU, Continued EIAU in 12 Clinics | Phase II: Non-responders to EIAU, Responders to Added LICF in 14 Clinics | Phase III: Non-responders to LICF+EIAU, Continued LICF | Phase III: Non-responders to LICF+EIAU, HICF Added | Phase II: LICF After Non-response to EIAU, Dropout Before Response to LICF Can be Determined | Phase I: EIAU, Dropout Before Response to EIAU Can be Determined | Total |
|---|---|---|---|---|---|---|---|---|
| Sex — Male | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Sex — Female | 68 | 16 | 18 | 24 | 24 | 1 | 1 | 152 |
| Sex — Unknown | 2 | 1 | 3 | 0 | 0 | 0 | 1 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Phase I: Responders to EIAU in 41 Clinics | Phase II: Non-responders to EIAU, Continued EIAU in 12 Clinics | Phase II: Non-responders to EIAU, Responders to Added LICF in 14 Clinics | Phase III: Non-responders to LICF+EIAU, Continued LICF | Phase III: Non-responders to LICF+EIAU, HICF Added | Phase II: LICF After Non-response to EIAU, Dropout Before Response to LICF Can be Determined | Phase I: EIAU, Dropout Before Response to EIAU Can be Determined | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 14 | 1 | 1 | 3 | 3 | 0 | 1 | 23 |
| Not Hispanic or Latino | 39 | 11 | 14 | 18 | 18 | 1 | 1 | 102 |
| Unknown or Not Reported | 17 | 6 | 6 | 3 | 3 | 0 | 0 | 35 |
| Race (NIH/OMB)(Participants) | Phase I: Responders to EIAU in 41 Clinics | Phase II: Non-responders to EIAU, Continued EIAU in 12 Clinics | Phase II: Non-responders to EIAU, Responders to Added LICF in 14 Clinics | Phase III: Non-responders to LICF+EIAU, Continued LICF | Phase III: Non-responders to LICF+EIAU, HICF Added | Phase II: LICF After Non-response to EIAU, Dropout Before Response to LICF Can be Determined | Phase I: EIAU, Dropout Before Response to EIAU Can be Determined | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 9 | 1 | 4 | 4 | 8 | 0 | 1 | 27 |
| White | 41 | 8 | 11 | 14 | 10 | 1 | 0 | 85 |
| More than one race | 1 | 0 | 0 | 1 | 3 | 0 | 1 | 6 |
| Unknown or Not Reported | 18 | 7 | 5 | 5 | 3 | 0 | 0 | 38 |
| Region of Enrollment(participants) | Phase I: Responders to EIAU in 41 Clinics | Phase II: Non-responders to EIAU, Continued EIAU in 12 Clinics | Phase II: Non-responders to EIAU, Responders to Added LICF in 14 Clinics | Phase III: Non-responders to LICF+EIAU, Continued LICF | Phase III: Non-responders to LICF+EIAU, HICF Added | Phase II: LICF After Non-response to EIAU, Dropout Before Response to LICF Can be Determined | Phase I: EIAU, Dropout Before Response to EIAU Can be Determined | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 70 | 18 | 21 | 24 | 24 | 1 | 2 | 160 |
| Clinic FQHC status(Participants) | Phase I: Responders to EIAU in 41 Clinics | Phase II: Non-responders to EIAU, Continued EIAU in 12 Clinics | Phase II: Non-responders to EIAU, Responders to Added LICF in 14 Clinics | Phase III: Non-responders to LICF+EIAU, Continued LICF | Phase III: Non-responders to LICF+EIAU, HICF Added | Phase II: LICF After Non-response to EIAU, Dropout Before Response to LICF Can be Determined | Phase I: EIAU, Dropout Before Response to EIAU Can be Determined | Total |
|---|---|---|---|---|---|---|---|---|
| Yes | 6 | 4 | 0 | 3 | 4 | 0 | 0 | 17 |
| No | 64 | 14 | 21 | 21 | 20 | 1 | 2 | 143 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — After data have been collected and study results published, de-identified data will be made available to other qualified researchers upon request, on a CD or other electronic means compatible with our systems. The request will be evaluated by the PIs to ensure that it meets reasonable standards of scientific integrity. We have use standard measures where possible in order to promote data sharing and integration into larger databases and to allow other researchers to analyze the data, including conducting meta-analyses. We will work on the data dictionary throughout the study. Data checking will occur regularly. We will submit primary results for publication by the end of the project period, and will have final de-identified datasets and data dictionaries available by CD within the required time frame.
Supporting information: Study protocol, Sap
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Michigan State University